Brain volume reductions in medication-naive patients with schizophrenia in relation to intelligence quotient

2012 ◽  
Vol 42 (9) ◽  
pp. 1847-1856 ◽  
Author(s):  
M. Rais ◽  
W. Cahn ◽  
H. G. Schnack ◽  
H. E. Hulshoff Pol ◽  
R. S. Kahn ◽  
...  

BackgroundGlobal brain abnormalities such as brain volume loss and grey- and white-matter deficits are consistently reported in first-episode schizophrenia patients and may already be detectable in the very early stages of the illness. Whether these changes are dependent on medication use or related to intelligence quotient (IQ) is still debated.MethodMagnetic resonance imaging scans were obtained for 20 medication-naive patients with first-episode schizophrenia and 26 matched healthy subjects. Volume measures of total brain grey and white matter, third and lateral ventricles and cortical thickness/surface were obtained. Differences between the groups were investigated, taking into account the effect of intelligence.ResultsMedication-naive patients showed statistically significant reductions in whole-brain volume and cerebral grey- and white-matter volume together with lateral ventricle enlargement compared to healthy subjects. IQ was significantly lower in patients compared to controls and was positively associated with brain and white-matter volume in the whole group. No significant differences in cortical thickness were found between the groups but medication-naive patients had a significantly smaller surface in the left superior temporal pole, Heschl's gyrus and insula compared to controls.ConclusionsOur findings suggest that brain volume loss is present at illness onset, and can be explained by the reduced surface of the temporal and insular cortex. These abnormalities are not related to medication, but IQ.

2013 ◽  
Vol 19 (9) ◽  
pp. 1175-1181 ◽  
Author(s):  
Angela Vidal-Jordana ◽  
Jaume Sastre-Garriga ◽  
Francisco Pérez-Miralles ◽  
Carmen Tur ◽  
Mar Tintoré ◽  
...  

Background: Investigation of atrophy data from a pivotal natalizumab trial has demonstrated an increased rate of volume loss, compared to placebo, after the first year of therapy. It was considered to be probably due to a pseudoatrophy effect. Objective: To assess grey and white matter volume changes and their relation to global brain volume changes and to baseline inflammation, for patients under natalizumab therapy. Methods: We selected 45 patients on natalizumab therapy for at least 24 months, with magnetic resonance imaging (MRI) scans at baseline, 12 and 24 months. We calculated the percentage brain volume change (PBVC) for the first and second year, using SIENA software. Grey and white matter fractions (GMF and WMF, respectively) for the first year were calculated with SPM5, using lesion masks. After quality checks, six patients were excluded. We studied the predictive variables of change in brain volumes. Results: The PBVC decrease was faster during the first year (−1.10% ± 1.43%), as compared to the second (−0.51% ± 0.96%) ( p = 0.037). These differences were more marked in patients with baseline gadolinium-enhancing lesions ( p = 0.005). Mean GMF and WMF changes during the first year of treatment were +1.15% (n.s.) and −1.72% ( p = 0.017), respectively. The presence of active lesions at baseline MRI predicted PBVC ( p = 0.022) and WMF change ( p = 0.026) during the first year of treatment, after adjusting for age and corticosteroid treatment. No predictors were found for GMF volume changes. Conclusion: Early brain volume loss during natalizumab therapy is mainly due to WMF volume loss and it is related to the inflammatory activity present at the onset of therapy. We found that the pseudoatrophy effect is mostly due to white matter volume changes.


2020 ◽  
Author(s):  
Sehoon Park ◽  
Soojin Lee ◽  
Yaerim Kim ◽  
Semin Cho ◽  
Kwangsoo Kim ◽  
...  

AbstractBackgroundAtrial fibrillation (AF) and brain volume loss are prevalent in older individuals. Further study investigating the causal effect of AF on brain volume is warranted.MethodsThis study was a Mendelian randomization (MR) analysis. The genetic instrument for AF was constructed from a previous genome-wide association study (GWAS) meta-analysis and included 537,409 individuals of European ancestry. The outcome summary statistics for quantile-normalized white or grey matter volume measured by magnetic resonance imaging were provided by the previous GWAS of 8426 white British UK Biobank participants. The main MR method was the inverse variance weighted method, supported by sensitivity MR analysis including MR-Egger regression and the weighted median method. The causal estimates from AF to white or grey matter volume were further adjusted for effects of any stroke or ischemic stroke by multivariable MR analysis.ResultsA higher genetic predisposition for AF (one standard deviation increase) was significantly associated with lower white matter volume [beta −0.128 (−0.208, −0.048)] but not grey matter volume [beta −0.041 (−0.101, 0.018)], supported by all utilized sensitivity MR analyses. The multivariable MR analysis indicated that AF is causally linked to lower white matter volume independent of the stroke effect.ConclusionsAF is a causative factor for white matter volume loss. The effect of AF on grey matter volume was inapparent in this study. A future trial is necessary to confirm whether appropriate AF management can be helpful in preventing cerebral white matter volume loss or related brain disorders in AF patients.


2008 ◽  
Vol 165 (4) ◽  
pp. 490-496 ◽  
Author(s):  
Monica Rais ◽  
Wiepke Cahn ◽  
Neeltje Van Haren ◽  
Hugo Schnack ◽  
Esther Caspers ◽  
...  

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2481-2481
Author(s):  
Soyoung Choi ◽  
Adam M Bush ◽  
Matt Borzage ◽  
Anand Joshi ◽  
Thomas D. Coates ◽  
...  

Abstract Background: Sickle cell disease (SCD) is a life-threatening genetic disease whose patients suffer from chronic anemia, hemolysis, vascular damage, and impaired cerebral blood flow that lead to early and cumulative neurological insults. Adverse effects associated with chronic anemia and hemolysis in SCD include progressive large vessel vasculopathy, stroke, silent cerebral infarctions, and ultimately, early mortality. Few studies have attempted to characterize the effects of this disease on brain morphometry and most have been limited to school age children, despite the progressive nature of the cerebrovascular disease. Thus, this study aims to quantify the hematological effects of SCD on brain morphometry in adolescents and young adults. Methods: 3D T1-weighted images (TE =3.8ms TR =8.3ms; resolution = 1mm3) were acquired on 25 clinically asymptomatic SCD patients (age=20.8 ± 6.7; F=13, M=12) and 26 ethnically matched control subjects (age=26.4 ± 7.7; F=17, M=9). MRI data were acquired on a 3T Philips Achieva (v.3.2.1) using an 8-channel head coil. All patients were recruited with informed consent or assent; the study was approved by the Institutional Review Board at Children's Hospital Los Angeles (CCI#11-00083). Exclusion criteria included pregnancy, previous overt stroke, acute chest, or pain crisis hospitalization within one month. T1-weighted images were processed using BrainSuite (brainsuite.org) in a semi-automated fashion to calculate whole brain gray matter volume (GMV), and white matter volume (WMV). Stepwise multivariate regression analysis was run on GMV and WMV against laboratory data and vital signs to find predictors of total brain volume. Laboratory data probed including complete blood counts and indices, quantitative hemoglobin electrophoresis, and markers of hemolysis (LDH, reticulocyte count, cell free hemoglobin). After correcting for age and sex, the remaining predictors of grey and white matter volume were used to probe for regional changes in brain volume through tensor based morphometry (Brain Suite Statistics Toolbox). Results: White matter, but not grey matter, was diffusely smaller in SCD patients. Sex, age (log transformed) and mean platelet volume (MPV) were the parameters retained in the multivariate model to predict GMV (r2=0.65; F ratio=28.9) where MPV had a positive correlation to GMV. Hemoglobin, sex, and MPV were found as predictors of WMV (r2=0.43; F ratio = 11.8) where both hemoglobin and MPV had a positive correlation to WMV. Using tensor based morphometry (TBM), both hemoglobin and MPV were positively associated with brain volume changes diffusely in the frontal, parietal, and temporal cortices (Figure 1). Hemoglobin had a strong localized effect on the subcortex (white matter and basal ganglia) (Figure 1) suggesting that anemia was associated with volume loss in these areas. MPV overall was found to have a strong effect on cortical morphology diffusely. Conclusion: Hemoglobin's relationship to brain volume and morphology suggests global white matter shrinkage due to anemia. The association is strongest in the phylogenetically younger portions of the brain and co-localizes with brain regions impacted by silent stroke. MPV was an unexpectedly strong predictor of cortical volumes in both SCD and control subjects. MPV is an indicator of platelet activation and is associated with ischemic stroke, hypertension, obstructive sleep apnea, and coronary artery syndromes in the general population, similar to C-reactive protein. However, the broad association of MPV and grey matter volumes in both SCD patients and controls, independently, suggests a developmental interplay between brain maturation and inflammatory signaling that requires further study. Disclosures Wood: Celgene: Consultancy; Ionis Pharmaceuticals: Consultancy; AMAG: Consultancy; Apopharma: Consultancy; Apopharma: Consultancy; Biomed Informatics: Consultancy; Biomed Informatics: Consultancy; AMAG: Consultancy; Celgene: Consultancy; Vifor: Consultancy; Ionis Pharmaceuticals: Consultancy; World Care Clinical: Consultancy; Vifor: Consultancy; World Care Clinical: Consultancy.


1996 ◽  
Vol 39 (7) ◽  
pp. 603
Author(s):  
R.B. Zipursky ◽  
E.K. Lambe ◽  
D. Goldbloom ◽  
J. Ridgley ◽  
D.J. Mikulis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document